-- Fresenius Kabi's APP Unit Starts Selling Version of AstraZeneca's Arimidex
-- Angela Cullen
-- 2010-06-29T05:17:23Z
-- http://www.bloomberg.com/news/2010-06-29/fresenius-kabi-s-app-unit-starts-selling-version-of-astrazeneca-s-arimidex.html

          
          
             Fresenius SE’s APP Pharmaceuticals
unit will start the sale of Anastrozole breast cancer pills in
the U.S. immediately after winning approval from regulators for
its version of AstraZeneca Plc’s Arimidex.  
 Sales of the branded product came to $916.8 million last
year, the companies said in a statement on Business Wire today.  
          
          


  


        